Cytoreductive nephrectomy in metastatic renal cancer — less is more

Cytoreductive nephrectomy in metastatic renal cancer — less is moreCytoreductive nephrectomy in metastatic renal cancer — less is more, Published online: 02 July 2018; doi:10.1038/s41571-018-0065-4CARMENA, a trial comparing the efficacy of sunitinib alone to that of nephrectomy followed by sunitinib in patients with primary metastatic renal cell carcinoma who require targeted therapy has demonstrated the non-inferiority of systemic therapy alone. The data provided by this and other studies argue for a lesser role of surgery in the management of these patients.

Source: Nature Clinical Practice Oncology - July 2, 2018 Category: Cancer & Oncology Authors: Axel Bex John Haanen Source Type: research